@canbridgepharma.com
Established in 2012, CANbridge is a leading China-based, global rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
Icon
JPEG
About
Description
CANbridge Pharmaceuticals Inc. They have a diverse drug portfolio, including three approved drugs and a pipeline of 11 assets. Their focus is on addressing prevalent rare disease and rare oncology indications that have significant unmet needs and market potential.
This includes disorders such as Hunter syndrome, lysosomal storage disorders, complement-mediated disorders, and neuromuscular diseases. CANbridge is also investing in next-generation gene therapies for rare genetic diseases. They have collaborations with renowned researchers and biotech companies, and are developing an adeno-associated virus (AAV) delivery platform.
Led by a management team with extensive experience in the rare disease field, CANbridge has a proven track record of achieving approval and commercialization of rare disease therapies globally. They are actively contributing to the rare disease industry in China and are recognized as a key player in shaping the rare disease ecosystem in the country
Company Type
Public Company
Company Size
201-500
Year Founded
2012
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories